Compare Illumina, Inc. (ILMN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Illumina, Inc. trades at $271.84 (market cap $40.95B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Illumina, Inc. is far larger — about 8.4× Travere Therapeutics Inc. Common Stock's market cap, and Illumina, Inc. is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 84 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ILMN | TVTX | |
|---|---|---|
Market Cap | $40.95B | $4.88B |
Volume | 1,893,606 | 1,668,577 |
Sector | Health | Health |
52-Week High | $293.69 | $67.52 |
52-Week Low | $93.00 | $26.79 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $42.31B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.76, down 1.77% today but near its 52-week high of $278.99. The stock has surged 94.9% YTD, supported by strong earnings beats and positive technical momentum. Recent quarterly results exceeded expectations with Q2 2026 EPS of $1.31 beating the $1.23 estimate. The company shows improving fundamentals with 2025 net income of $850 million and robust operating cash flow of $1.08 billion.
ILMN presents growth potential through AI integration and S&P 500 inclusion, but faces risks from China headwinds and elevated valuations. Analyst consensus remains bullish with 54% buy ratings, though the $241 consensus price target suggests limited upside. Key catalysts include continued sequencing growth and margin expansion, while competition and cost volatility remain concerns.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
